ELV250117C250000
- 136.30
- 0.000.00%
Elevance Health Newsroom
Bernstein Maintains Elevance Health(ELV.US) With Buy Rating, Raises Target Price to $511
Jefferies Maintains Elevance Health(ELV.US) With Buy Rating, Raises Target Price to $461
TD Cowen Maintains Elevance Health(ELV.US) With Buy Rating, Maintains Target Price $484
TD Cowen Maintains Elevance Health(ELV.US) With Buy Rating, Maintains Target Price $484
Elevance Health Buy Rating: Growth Potential Despite Cost Challenges
Stephens Adjusts Price Target on Elevance Health to $430 From $440
Elevance Health Is Maintained at Overweight by Barclays
Elevance Health Analyst Ratings
Barclays Adjusts Elevance Health Price Target to $512 From $501, Maintains Overweight Rating
Truist Financial Maintains Elevance Health(ELV.US) With Buy Rating, Maintains Target Price $480
Cantor Fitzgerald Maintains Elevance Health(ELV.US) With Buy Rating, Cuts Target Price to $485
A Quick Look at Today's Ratings for Elevance Health(ELV.US), With a Forecast Between $465 to $512
Deutsche Bank Cuts Elevance Health Price Target to $465 From $467, Maintains Buy Rating
RBC Capital Keeps Their Buy Rating on Elevance Health (ELV)
Analysts' Opinions Are Mixed on These Healthcare Stocks: Elevance Health (ELV), Intuitive Surgical (ISRG) and Walgreens Boots Alliance (WBA)
Cautious Hold Recommendation on Elevance Health Amidst Medicare Growth and Medicaid Cost Challenges
Morgan Stanley Reaffirms Their Hold Rating on Elevance Health (ELV)
Stephens Downgrades Elevance Health(ELV.US) to Hold Rating, Cuts Target Price to $440
Stephens Downgrades Elevance Health to Equalweight From Overweight, Adjusts Price Target to $440 From $520
Barclays Maintains Elevance Health(ELV.US) With Buy Rating, Maintains Target Price $501